Clinical Scorecard: Mendelian Randomization Reveals Protein Associations with Neurodegenerative Disorders
At a Glance
Category
Detail
Condition
Neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis
Key Mechanisms
Protein abundance in plasma influencing disease risk via pathways involving complement system, microglia, lysosomes, interleukin-6 pathway, blood–brain barrier integrity, astrocytes, oligodendrocytes, and innate immune system
Target Population
Individuals of European ancestry from large population biobanks
Care Setting
Research and clinical biomarker discovery settings focusing on neurodegenerative disease pathogenesis and drug target identification
Key Highlights
Identification of 169 statistically significant protein–disease associations from 13,377 tested, with 50 unique protein–disease pairs showing strong co-localization evidence.
Discovery of 23 novel protein–disease genetic loci not previously reported by genome-wide association studies.
Demonstration that plasma protein abundance (e.g., APOE, PILRA, PILRB) correlates with brain imaging phenotypes such as subcortical volumes and white matter hyper-intensities.
Guideline-Based Recommendations
Diagnosis
Utilize plasma proteomic profiling via high-throughput platforms (Olink, SomaScan) to identify protein biomarkers associated with neurodegenerative diseases.
Incorporate Mendelian randomization and co-localization analyses to strengthen causal inference between protein levels and disease risk.
Management
Target identified proteins and pathways (e.g., complement system, interleukin-6 pathway, lysosomal function, blood–brain barrier integrity) for therapeutic development.
Consider proteins as potential drug targets given their role in disease pathogenesis and FDA approval precedence for protein-targeted therapies.
Monitoring & Follow-up
Monitor plasma protein levels as biomarkers for disease progression or therapeutic response in neurodegenerative disorders.
Use brain imaging phenotypes correlated with protein abundance to assess disease impact and progression.
Risks
Recognize limitations of transcriptome-wide MR approaches using eQTLs due to poor correlation with protein abundance.
Account for potential confounding by linkage disequilibrium through co-localization analyses in genetic studies.
Patient & Prescribing Data
Patients with neurodegenerative diseases or at risk, primarily of European ancestry
Approximately 75% of FDA-approved medications target human proteins, underscoring the therapeutic potential of proteins identified through proteogenomic studies for neurodegenerative conditions.
Clinical Best Practices
Leverage large-scale genomic and proteomic data integration to identify novel biomarkers and drug targets in neurodegenerative diseases.
Apply two-sample cis Mendelian randomization combined with co-localization to minimize confounding and infer causality.
Incorporate multi-platform proteomic measurements (Olink and SomaScan) to enhance protein coverage and validation.
Explore associations between plasma protein levels and brain imaging phenotypes to understand disease mechanisms.
